Sweden participates in clinical WHO study

Because more than 100 countries are taking part in the WHO study Solidarity Trial, the patient base is large. This makes it quicker to see whether any of the preparations are effective, and can begin to be used to treat the disease.

The Swedish Government recently appointed Soo Aleman, Consultant Physician at the Karolinska University Hospital and Associate Professor at Karolinska Institutet, to be the national coordinator for the Swedish part of the study. The Swedish Research Council will fund Swedish participation, as soon as the investment is formalized in the regulatory letter.

“It is important for Sweden to be part of the international study. Patients in Sweden who have suffered severe COVID-19 can now get access to potentially effective medicines. In the long term we will obtain greater knowledge of what is effective, which will also benefit patients who are not part of the study,” says Jan-Ingvar Jönsson, Secretary General of the Scientific Council for Medicine and Health and Clinical Therapy Research at the Swedish Research Council.

About the studie Solidarity trial on WHO´s website